CanSino Biologics (06185.HK): Inhaled tuberculosis vaccine launched Phase I clinical trial in Indonesia and completed the enrollment of the first trial participant.

Smart Finance App News, CanSino Biologics (06185.HK) announced that the inhaled tuberculosis vaccine (type 5 adenovirus vector) developed by the company has recently officially started Phase I clinical trials in Indonesia, and the first participant has been enrolled in the Phase I clinical trial.